Document Detail

The efficacy of alefacept in the treatment of chronic plaque psoriasis.
MedLine Citation:
PMID:  15668749     Owner:  NLM     Status:  MEDLINE    
With the completion of several phase 2 and phase 3 clinical studies, the efficacy and tolerability of alefacept in patients with chronic plaque psoriasis is now well studied. The majority of patients treated with a single course of intravenous or intramuscular alefacept experienced a clinically meaningful response. The efficacy of alefacept correlated with its ability to selectively target and reduce the number of pathogenic memory T cells. A second course of alefacept resulted in further clinical improvement, with increasing response rates and prolonged response duration following treatment cessation. Subpopulation analyses demonstrated that alefacept is effective in a broad spectrum of patients with psoriasis, regardless of disease severity, history of and response to prior antipsoriatic treatment, or whether patients are refractory to or have contraindications to other systemic psoriasis therapies or phototherapy.
Kenneth B Gordon; Jayme Valentine
Related Documents :
2144249 - Topical ketoconazole for infantile seborrhoeic dermatitis.
19710549 - Topical treatment of psoriasis.
16307659 - Plasma cell balanitis treated with tacrolimus 0.1%.
22174999 - Bevacizumab injection in patients with age-related macular degeneration associated with...
11550079 - 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anter...
23208059 - Correlation among systemic inflammatory parameter, occurrence of delayed neurological d...
21953329 - Perioperative infusion of dexmedetomidine at a high dose reduces postoperative analgesi...
9607879 - Subureteric polydimethylsiloxane injection in the treatment of vesico-ureteric reflux.
2312539 - Spondylolisthesis treated by a single-stage operation combining decompression with in s...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cutaneous medicine and surgery     Volume:  8 Suppl 2     ISSN:  1203-4754     ISO Abbreviation:  J Cutan Med Surg     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2005-01-25     Completed Date:  2005-07-25     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9614685     Medline TA:  J Cutan Med Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3-9     Citation Subset:  IM    
Division of Dermatology, Loyola University Medical Center, Maywood, IL 60153, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Chronic Disease
Double-Blind Method
Middle Aged
Multicenter Studies as Topic
Psoriasis / drug therapy*
Randomized Controlled Trials as Topic
Recombinant Fusion Proteins / therapeutic use*
Reg. No./Substance:
0/Recombinant Fusion Proteins; ELK3V90G6C/alefacept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dietary oxysterols induce in vivo toxicity of coronary endothelial and smooth muscle cells.
Next Document:  The remittive effects of alefacept.